
## Hua-Xia Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/866435/publications.pdf Version: 2024-02-01



ΗΠΑ-ΧΙΑ ΥΑΝΟ

#	Article	IF	CITATIONS
1	Cancer occurrence after SLE: effects of medication-related factors, disease-related factors and survival from an observational study. Rheumatology, 2023, 62, 659-667.	1.9	1
2	Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4–related disease. Rheumatology, 2022, 61, 2197-2209.	1.9	3
3	Predictive Value of Echocardiographic Strain for Myocardial Fibrosis and Adverse Outcomes in Autoimmune Diseases. Frontiers in Cardiovascular Medicine, 2022, 9, 836942.	2.4	4
4	The five major autoimmune diseases increase the risk of cancer: epidemiological data from a largeâ€scale cohort study in China. Cancer Communications, 2022, 42, 435-446.	9.2	22
5	Fibroblast Activation Protein–Targeted PET/CT with <sup>68</sup> Ga-FAPI for Imaging IgG4-Related Disease: Comparison to <sup>18</sup> F-FDG PET/CT. Journal of Nuclear Medicine, 2021, 62, 266-271.	5.0	110
6	Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review. Clinical Reviews in Allergy and Immunology, 2021, 60, 17-30.	6.5	15
7	Distinctive Clinical Characteristics and Outcome of ILD-Onset Rheumatoid Arthritis and ACPA-Positive ILD: a Longitudinal Cohort of 282 Cases. Clinical Reviews in Allergy and Immunology, 2021, 60, 46-54.	6.5	10
8	Clinical manifestations and long-term prognosis of Good syndrome: Results from a single-center cohort study from China. Modern Rheumatology, 2021, 31, 1019-1024.	1.8	2
9	Inflammatory Arthritis Induced by Anti-Programmed Death-1 Shown in 68Ga-FAPI PET/CT in a Patient With Esophageal Carcinoma. Clinical Nuclear Medicine, 2021, 46, 431-432.	1.3	23
10	Clinical recommendations for perioperative immunotherapyâ€induced adverse events in patients with nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 1469-1488.	1.9	7
11	Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer. Frontiers in Oncology, 2021, 11, 537735.	2.8	5
12	Comprehensive T-cell receptor repertoire of Chinese lung cancer patients related with age Journal of Clinical Oncology, 2021, 39, e21076-e21076.	1.6	0
13	Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. Nature Communications, 2021, 12, 4977.	12.8	73
14	Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 730320.	4.8	39
15	Novel autoantibodies identified in ACPA-negative rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 739-747.	0.9	27
16	Complement C1q synergizes with PTX3 in promoting NLRP3 inflammasome over-activation and pyroptosis in rheumatoid arthritis. Journal of Autoimmunity, 2020, 106, 102336.	6.5	82
17	Usefulness of Myocardial Strain and Twist for Early Detection of Myocardial Dysfunction in Patients With Autoimmune Diseases. American Journal of Cardiology, 2020, 125, 475-481.	1.6	6
18	Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis. Journal of Autoimmunity, 2020, 107, 102360.	6.5	102

Hua-Xia Yang

#	Article	IF	CITATIONS
19	Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. Clinical Immunology, 2020, 213, 108377.	3.2	44
20	Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Scientific Reports, 2020, 10, 4910.	3.3	36
21	Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development. Journal of Autoimmunity, 2020, 109, 102440.	6.5	27
22	Comprehensive TCR repertoire analysis of CD4+ T-cell subsets in rheumatoid arthritis. Journal of Autoimmunity, 2020, 109, 102432.	6.5	29
23	EZH2 deficiency attenuates Treg differentiation in rheumatoid arthritis. Journal of Autoimmunity, 2020, 108, 102404.	6.5	42
24	Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Medicine, 2020, 18, 87.	5.5	189
25	Genetic profiling and TCR repertoire feature of synchronous multiple primary lung carcinomas Journal of Clinical Oncology, 2020, 38, e21031-e21031.	1.6	Ο
26	Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. Annals of Translational Medicine, 2020, 8, 1415.	1.7	0
27	Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. Annals of Translational Medicine, 2020, 8, 1415-1415.	1.7	2
28	Standardized patient methodology in mainland China: a nationwide survey. BMC Medical Education, 2019, 19, 214.	2.4	5
29	Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib. Targeted Oncology, 2019, 14, 159-168.	3.6	33
30	The efficacy and safety of antithrombotic therapy in patients with positive antiphospholipid antibodies receiving invasive procedures: experience from a single tertiary center. Clinical Rheumatology, 2019, 38, 1897-1904.	2.2	4
31	Obstructive uropathy associated with rheumatoid arthritis successfully treated with steroids and immunosuppressive therapy. Medicine (United States), 2019, 98, e18415.	1.0	2
32	Clinical characteristics and risk factors for overlapping rheumatoid arthritis and Sjögren's syndrome. Scientific Reports, 2018, 8, 6180.	3.3	18
33	Cerebellar involvement in patients withprimary Sjögren's syndrome: diagnosis and treatment. Clinical Rheumatology, 2018, 37, 1207-1213.	2.2	9
34	Renal involvement in primary Sjögren's syndrome: A retrospective study of 103 biopsyâ€proven cases from a single center in China. International Journal of Rheumatic Diseases, 2018, 21, 223-229.	1.9	30
35	Exploring the association between somatic molecular features and tumor mutation burden in 513 non–small-cell lung cancer Journal of Clinical Oncology, 2018, 36, 12101-12101.	1.6	1
36	Visfatin mediates doxorubicin resistance in human non–smallâ€cell lung cancer <i>via</i> Aktâ€mediated upâ€regulation of <scp>ABCC</scp> 1. Cell Proliferation, 2017, 50, .	5.3	21

Hua-Xia Yang

#	Article	IF	CITATIONS
37	Pitfalls of PACNS: A Rare Case of Central Nervous System Vasculitis Associated with Toxoplasmosis. Journal of Rheumatology, 2017, 44, 1290-1291.	2.0	Ο
38	Long noncoding RNA MALAT-1 is a novel inflammatory regulator in human systemic lupus erythematosus. Oncotarget, 2017, 8, 77400-77406.	1.8	72
39	Chemotaxis of VÎ 2 T cells to the joints contributes to the pathogenesis of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 2075-2084.	0.9	31
40	Temozolomide encapsulated and folic acid decorated chitosan nanoparticles for lung tumor targeting: improving therapeutic efficacy both <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2017, 8, 111318-111332.	1.8	23
41	Down-regulation of microRNA-26b modulates non-small cell lung cancer cells chemoresistance and migration through the association of PTEN. Acta Biochimica Et Biophysica Sinica, 2015, 47, 530-538.	2.0	25
42	Pregnancy-Related Systemic Lupus Erythematosus: Clinical Features, Outcome and Risk Factors of Disease Flares — A Case Control Study. PLoS ONE, 2014, 9, e104375.	2.5	58
43	Are CD4+CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?. Arthritis Research and Therapy, 2009, 11, R153.	3.5	84